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patients (7%) died: 2 of disease progression and 2 of other 
causes. Mean and median time-to-progression are 12.1 and 
9.8 months respectively (range 2-53). 
 
Conclusion: Re-EBRT using stereotactic approach is a feasible 
option for local prostate cancer recurrence, achieving tumour 
control in 45% of the patients and an acceptable progression-
free interval. Toxicity of re-EBRT appeared to be very low. 
Future studies are needed to identify those patients who 
would benefit the most from this treatment. 
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Purpose or Objective: to evaluate the outcomes in 
intermediate risk prostate cancer treated with 
hypofractionated radiotherapy (HyRT) 
 
Material and Methods: Between March 2007 and March 2015, 
145 patients affected by intermediate risk (T2b–T2c prostate 
cancer or Gleason Score equal to 7 or pre-treatment PSA 
value ranging from 10 to 20 ng/mL) prostate cancer were 
treated with HyRT. The median age at diagnosis was 74 years 
(range 53-88). A pre-treatment CT scan with 2.5 mm slices 
was obtained. MRI was used to better delineate the Clinical 
Target Volume (CTV) when available. The CTV1 included the 
prostate plus seminal vesicles (SSVV) and the CTV2 the 
prostate alone. Planning Target Volumes (PTV1 and PTV2, 
respectively) were generated with 8 mm margin in all 
directions except posteriorly where a 6 mm expansion was 
adopted in the first 36 patients. A 5 mm expansion in all 
direction was used in the other patients as daily kv Cone 
Beam CT was used to verify the patient position because of 
an implementation of the linear accelerator. A 3D-CRT and a 
15 MV photons linear accelerator was used to deliver the 
treatment. The PTV1 received 43.8 Gy in 12 fractions and the 
PTV2 received 54.75 Gy in 15 fractions, three times a week in 
order to avoid an excess of acute toxicity. Neoadjuvant, 
concomitant and adjuvant ADT was administered for a total 
of 9 months and was started 3 months before RT. 
 
Results: After a median follow-up of 52.4 months (range 7 to 
95 months), 11 patients (7.6%) died, of whom 9 for 
intercurrent disease and 2 (1.3%) for PCa. The 5-year OS was 
90.1% (95%CI 84.2-97.6%) and the 5-year CSS was 98.6% 
(95%CI 95.4-100%). Fourteen patients (9.7%) developed 
biochemical recurrence after a median follow up of 30.5 
months (95% CI 28.5 to 32.5 months). Of these patients, 
thirteen (9.0%) had also a clinical detectable disease while 
the remaining patient presented only biochemical 
recurrence. The 5y-bRFS was 88.8% (95%CI 82.8-95.4%). 
Among the 13 patients with clinical recurrence, 7 (53.8%) had 
local recurrence, 2 (15.4%) developed distant metastases, 
and 4 (30.8%) had both local recurrence and distant 
metastases. Acute genito-urinary (GU) toxicity of grade 1 
occurred in 74 patients (51.0%), grade 2 in 15 patients 
(10.3%) and grade 3 in 2 patients (1.3%). Acute gastro-
intestinal (GI) toxicity of grade 1 were observed in 27 
patients (18.6%), grade 2 in 12 patients (8.2%). None 
developed acute GI toxicity of grade 3 or 4. Late GU toxicity 
occurred as follows: grade 1 in 51 patients (35.2%), grade 2 in 
12 patients (8.2%), grade 3 in 2 patients (1.3%). Late GI 
toxicity of grade 1 was observed in 18 patients (12.4%), grade 
2 in 6 patients (4.1%) and grade 3 in 1 patient (0.7%). 
 
Conclusion: The hypofractionated schedule used is well 
tolerated with a low rate of acute and late grade ≥ 2 
gastrointestinal and genitourinary toxicities. 
Hypofractionation is useful to obtain high rate of tumor 
control but a longer follow-up is needed for definitive 
conclusion. 
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Purpose or Objective: In the context of the multi-
institutional research project “Carbon ions boost followed by 
pelvic photon intensity modulated radiotherapy for high risk 
prostate cancer”, Contouring Guidelines (CG) for target 
volumes and Organs At Risk (OARs) were commonly defined 
based on National/International standards and local 
experiences. Intra- and inter-institutional variability was 
evaluated within a contouring dummy-run and a graphical 
tool was developed to assist the Radiation Oncologists (ROs) 
in the standardization of the contouring. 
 
Material and Methods: CT and MR images of 5 prostate 
patients were randomly chosen. Seven ROs belonging to the 
three Institutes involved in the project were assigned to 
independently contour targets (prostate (GTV-P), seminal 
vesicles (CTV-VS) and pelvic lymph nodes (CTV-N) and OARs 
(rectum (R), bladder (B), femoral heads (FH), small bowel 
(SB) , penile bulb (PB) and anal canal (AC). The registration 
between CT and MR images was only used to contour GTV-P 
and PB. The contours were compared by means of the DICE 
Index (defined as 2*(A∩B)/(A+B), where A e B are the 
volumes in comparison), as provided by the commercial 
software VODCA (MSS, v.5.4.0). For each structure, the 
Global DICE Index (GDI) was calculated as the average value 
for all the ROs and the patients and then compared with the 
DICE Index of the individual ROs: an individual DICE Index 
lower than the corresponding GDI (or lower than a threshold 
value of 0.9 for GDI > 0.9) was recorded as “disagreement” 
and reported in a graphical tool (Figure 1) that qualitatively 
shows intra- and inter-institutional variability. 
 
Results: The resulting GDI are reported in Table 1. A visual 
analysis of the contours on the CT images showed that the 
poor quality GDI for CTV-VS and AC were due both to a not 
strict application of the CG by the ROs of the different 
Institutes and to the small volume of those structures. The 
other results were instead attributable to random variation in 
the contouring. The graphical tool clearly showed that inter-
institutional variability was predominant compared to intra-
institutional variability both for targets and OARs. 
Nevertheless, some disagreement was found even between 
ROs of the same Institute. 
 
